{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:00:43Z","timestamp":1790586043337,"version":"4.1.0"},"reference-count":22,"publisher":"Georg Thieme Verlag KG","issue":"07","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gesundheitswesen"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Das Internetportal embryotox.de informiert evidenzbasiert, kostenlos und\nindustrieunabh\u00e4ngig zur Arzneimitteltherapiesicherheit in Schwangerschaft\nund Stillzeit. Es wird von mehr als f\u00fcnf Millionen Nutzer*innen pro Jahr\nbesucht. Im Rahmen einer durch den G-BA Innovationsfonds gef\u00f6rderten\nMixed-Methods-Studie wurde die Funktion von embryotox.de in der\nVersorgungspraxis untersucht. Diese Teilauswertung konzentriert sich auf die\nNutzung durch die Apothekerschaft.<\/jats:p>\n                  <jats:p>Die Datenerhebung erfolgte mittels zweier Online-Frageb\u00f6gen\n(Multiple-Choice-Antworten oder Likert-Skala von 0=\u201e\u00fcberhaupt nicht\u201c bis\n10=\u201evollst\u00e4ndig\u201c). Der erste Fragebogen enthielt Fragen zu\nNutzercharakteristika, klinischer Situation, Verst\u00e4ndlichkeit der\nArzneimittelinformationen und Konsequenzen der Nutzung, im zweiten wurden\ntypische Situationen der Nutzung und Verwendung der abgerufenen\nInformationen erfragt. F\u00fcr die vorliegende Teilanalyse wurden alle von\nApotheker*innen beantworteten Frageb\u00f6gen mittels deskriptiver Statistik\nausgewertet.<\/jats:p>\n                  <jats:p>Insgesamt 550 Apotheker*innen f\u00fcllten Online-Fragebogen 1 aus, davon\narbeiteten 87,3% (n=480\/550) in \u00f6ffentlichen Apotheken. Am h\u00e4ufigsten wurde\nzu Medikamenten gegen Husten und Erk\u00e4ltungssymptome (19,3%, n=106\/550)\nrecherchiert sowie zu nicht-opioiden Analgetika (16,9%, n=93\/550). Bei 57,1%\n(n=314\/550) \u00e4nderte sich durch diese Recherche die Risikobewertung des\nArzneimittels. Die Verst\u00e4ndlichkeit der Informationen wurde im Durchschnitt\nmit 9,25 (Likert-Skala von 0 bis 10) bewertet. 79 Apotheker*innen f\u00fcllten\nOnline-Fragebogen 2 aus. 93,7% (n=74\/79) fanden embryotox.de hilfreich, um\nverunsicherte Patientinnen zu informieren und gegebenenfalls zu beruhigen.\nWeiterhin nutzten sie embryotox.de, um ausgew\u00e4hlte Informationen an\nPatientinnen weiterzugeben (79,7%, n=63\/79), um \u00e4rztlich verordnete\nMedikamente vor der Abgabe zu \u00fcberpr\u00fcfen (57,0%, n=45\/79) und um bei\nkritischen Arzneimitteln R\u00fccksprache mit verschreibenden \u00c4rztinnen bzw.\n\u00c4rzten zu halten (58,2%, n=46\/79).<\/jats:p>\n                  <jats:p>Apotheker*innen informieren sich zur Vertr\u00e4glichkeit in Schwangerschaft und\nStillzeit bei embryotox.de sowohl zu rezeptfreien Pr\u00e4paraten (v.\u2009a. gegen\nakute Beschwerden) als auch zu verordneten Arzneimitteln. Damit \u00fcben sie\neine wichtige Kontroll- und Beratungsfunktion bei der Arzneimittelversorgung\nSchwangerer und Stillender aus, die durch embryotox.de wesentlich\nunterst\u00fctzt wird.<\/jats:p>","DOI":"10.1055\/a-2715-1040","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:09:07Z","timestamp":1763597347000},"page":"462-469","source":"Crossref","is-referenced-by-count":0,"title":["Das Internetportal embryotox.de und seine Nutzung durch\nApothekerinnen und Apotheker"],"prefix":"10.1055","volume":"88","author":[{"given":"Ariane","family":"Wahli\u00df","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Klinische Pharmakologie und Toxikologie, Pharmakovigilanz-\nund Beratungszentrum f\u00fcr Embryonaltoxikologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin\nBerlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Klinische Pharmakologie und Toxikologie, Pharmakovigilanz-\nund Beratungszentrum f\u00fcr Embryonaltoxikologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin\nBerlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelin","family":"Beck","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Klinische Pharmakologie und Toxikologie, Pharmakovigilanz-\nund Beratungszentrum f\u00fcr Embryonaltoxikologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin\nBerlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Harms","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Klinische Pharmakologie und Toxikologie, Pharmakovigilanz-\nund Beratungszentrum f\u00fcr Embryonaltoxikologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin\nBerlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Breuning","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Sozialmedizin und Epidemiologie, Medizinische Hochschule\nBrandenburg Theodor Fontane, Brandenburg an der Havel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Holmberg","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Sozialmedizin und Epidemiologie, Medizinische Hochschule\nBrandenburg Theodor Fontane, Brandenburg an der Havel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Schaefer","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Klinische Pharmakologie und Toxikologie, Pharmakovigilanz-\nund Beratungszentrum f\u00fcr Embryonaltoxikologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin\nBerlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Onken","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Klinische Pharmakologie und Toxikologie, Pharmakovigilanz-\nund Beratungszentrum f\u00fcr Embryonaltoxikologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin\nBerlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Dathe","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Klinische Pharmakologie und Toxikologie, Pharmakovigilanz-\nund Beratungszentrum f\u00fcr Embryonaltoxikologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin\nBerlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11096-013-9864-y","article-title":"Adherence to medication for chronic disorders during pregnancy: results from a\nmultinational study","volume":"36","author":"A Lupattelli","year":"2014","journal-title":"Int J Clin Pharm"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.seizure.2022.06.002","article-title":"Delivery of care, seizure control and medication adherence in women with\nepilepsy during pregnancy","volume":"100","author":"A Askarieh","year":"2022","journal-title":"Seizure"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.preghy.2021.06.002","article-title":"Adherence to anti-hypertensive medication in pregnancy","volume":"25","author":"A Helou","year":"2021","journal-title":"Pregnancy Hypertens"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00228-017-2351-y","article-title":"Drug safety in pregnancy: the German Embryotox institute","volume":"74","author":"K Dathe","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18094392","article-title":"Impact of Pharmacists\u2019 Interventions and Patients\u2019 Decision on Health Outcomes\nin Terms of Medication Adherence and Quality Use of Medicines among Patients\nAttending Community Pharmacies: A Systematic Review","volume":"18","author":"K Rajiah","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-002594","article-title":"Medicines information needs during pregnancy: a multinational comparison","volume":"3","author":"K H\u00e4meen-Anttila","year":"2013","journal-title":"BMJ Open"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00228-009-0744-2","article-title":"Perception of risk regarding the use of medications and other exposures during\npregnancy","volume":"66","author":"H Nordeng","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/dhps.S412786","article-title":"Predictors of Using Pharmacists as a Medication Safety Information Resource\nAmong Women of Reproductive Age","volume":"16","author":"M K Awuonda","year":"2024","journal-title":"Drug Healthc Patient Saf"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2174\/1381612825666190321110420","article-title":"Women\u2019s Beliefs About Medicines and Adherence to Pharmacotherapy in Pregnancy:\nOpportunities for Community Pharmacists","volume":"25","author":"M Ceulemans","year":"2019","journal-title":"Curr Pharm Des"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1177\/1715163514552558","article-title":"Comparison of pharmacist knowledge, perceptions and training opportunities\nregarding maternal-fetal medicine in Canada, Qatar and Uganda","volume":"147","author":"S Bains","year":"2014","journal-title":"Can Pharm J (Ott)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.yebeh.2008.10.018","article-title":"An evaluation of pharmacists\u2019 knowledge of women\u2019s issues in epilepsy","volume":"14","author":"J W McAuley","year":"2009","journal-title":"Epilepsy Behav"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.2042-7174.2001.tb01024.x","article-title":"Community pharmacists\u2019 views and experiences of counter-prescribing in\npregnancy","volume":"9","author":"SM K Hutchinson","year":"2011","journal-title":"International Journal of Pharmacy Practice"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/pds.954","article-title":"Drug counselling in pregnancy: an opinion survey of French community\npharmacists","volume":"13","author":"C Damase-Michel","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.midw.2016.06.003","article-title":"Pharmacists counselling of pregnant women: Web-based, comparative study between\nSerbia and Norway","volume":"40","author":"M Odalovi\u0107","year":"2016","journal-title":"Midwifery"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1023\/b:phar.0000035881.17853.e0","article-title":"Needs and use of drug information sources in community pharmacies: a\nquestionnaire based survey in German-speaking Switzerland","volume":"26","author":"S Zehnder","year":"2004","journal-title":"Pharm World Sci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/ajo.13071","article-title":"Utilisation of a NSW teratology information service by pharmacists and patients\nreferred by a pharmacist from 2000 to 2018","volume":"60","author":"H E Ritchie","year":"2020","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"ref18","first-page":"e377","article-title":"Teratogen information service for pharmacists: a pilot study","volume":"18","author":"M P Tan","year":"2011","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e0262254","DOI":"10.1371\/journal.pone.0262254","article-title":"An exploratory survey on community pharmacists\u2019 service provision for pregnant\nand lactating women in Sharjah, United Arab Emirates","volume":"17","author":"Z A Akkad","year":"2022","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e018980","DOI":"10.1136\/bmjopen-2017-018980","article-title":"Community pharmacists\u2019 services for women during pregnancy and breast feeding in\nKuwait: a cross-sectional study","volume":"8","author":"A Albassam","year":"2018","journal-title":"BMJ Open"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/ijpp\/riae057.","article-title":"Nausea and vomiting in pregnancy: a cross-sectional study of community\npharmacists in the UK","author":"B Payne","year":"2024","journal-title":"Int J Pharm Pract"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1177\/1049732317732027","article-title":"Improving Safe Use of Medications During Pregnancy: The Roles of Patients,\nPhysicians, and Pharmacists","volume":"27","author":"M M Lynch","year":"2017","journal-title":"Qual Health Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.sapharm.2019.12.010","article-title":"Community pharmacists\u2019 attitudes, barriers, knowledge and counseling practice\nwith regard to preconception, pregnancy and lactation","volume":"16","author":"M Ceulemans","year":"2020","journal-title":"Res Social Adm Pharm"}],"container-title":["Das Gesundheitswesen"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2715-1040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T08:50:10Z","timestamp":1790585410000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2715-1040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":22,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2026,7,8]]},"published-print":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2715-1040","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0941-3790","1439-4421"],"issn-type":[{"value":"0941-3790","type":"print"},{"value":"1439-4421","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]}}}